Eloralintide
Phase 3 trials began around the end of 2025.
A weekly injection that copies , the fullness hormone released with insulin. Amylin drugs are being developed as a gentler alternative or partner to . A made by Eli Lilly, also called LY3841136.
What the evidence shows
Side effects and risks
Who should avoid it: Anyone outside a clinical trial.
How it works
- Where it acts
- Amylin receptors in the brainstem.
- What it changes
- Stronger fullness signals and a slower-emptying stomach.
- What people notice
- Less appetite and weight loss in phase 2 trials. Stomach side effects were reported.
How it has been given in trials
Weekly injection under the skin, 1 mg to 9 mg. There is no approved dose.
Getting it in the United States
The legal route for Eloralintide
Not approved. The only lawful way to get it is to join a clinical trial.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
More contextWhat public figures say, videos and articles and when options run out
What experts and influencers say
Paraphrased from the linked sources.
Called the phase 2 weight loss clinically meaningful and said most lost weight was fat. Also said longer studies are needed to learn the effect on cardiovascular risk.
Source: Medical News Today, 2025-11
Liana BillingsWebsiteRecommends
Money: Trial funded by Eli Lilly
Photo source: doximity.com
Found the slow-escalation data promising, with fewer gut side effects than rival drugs showed in another trial, but said phase 3 results, access and cost remain open questions.
Source: Healio, 2025-12
Deborah HornSourceMixed view
Said the drug gave dose-dependent weight loss with acceptable tolerability and could widen options for people who do not get enough benefit from current treatments.
Source: Healio, 2025-12
Harold BaysWebsiteRecommends
Photo source: overcomingobesity.eventscribe.net
Was cautiously optimistic but warned that early-phase results do not guarantee a usable therapy, and that long-term safety and durability are unknown.
Source: Medical News Today, 2025-11
Jeffrey KraftWebsiteMixed view
Photo source: getcare.hackensackmeridianhealth.org
Said the drug may become an alternative to incretin drugs with better tolerability, and an add-on for people who need more weight loss.
Source: Consultant Live, 2025-11
Kenneth CusterWebsiteRecommends
Money: Eli Lilly executive
Photo source: theorg.com
Called the results promising but urged caution, noting that some risks only appear after a drug is used by many people.
Source: Fox News, 2025-11
Whitney Di BonaWebsiteMixed view
Photo source: drugwatch.com
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Lilly's new weight loss drug shows promise in mid-stage trial
News report on the phase 2 eloralintide trial: a weekly amylin-type injection, up to about 20 percent weight loss, and Lilly's late-stage plans.
Easy mainstream introduction to Lilly's amylin-based candidate.
Eli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3
Nick Paul Taylor, reporter
Trade-press rundown of the 48-week phase 2 results for eloralintide, including the weight loss range versus placebo and how slower dose escalation eased side effects.
Compact, number-focused summary of the trial.
New weight-loss shot shows major fat reduction, but experts urge caution
Melissa Rudy, health reporter
Pairs eloralintide phase 2 results with outside warnings that rare side effects emerge only after wide use and new drugs may not beat old ones.
The cautious counterpoint to the headline numbers.
When options run out
Uses people turn to when standard treatment has failed.
Option for poor responders to incretins
- Who
- People who cannot tolerate or do not lose enough weight on GLP-1 based drugs.
- Evidence
- Phase 2 trial in 263 adults showed weight loss with mostly mild gut effects and fatigue. It did not enrol incretin failures specifically, so this is expert expectation only.
- Route
- ENLIGHTEN phase 3 programme
Source: Healio, 2025-12
Delaying type 2 diabetes in prediabetes
- Who
- Adults with obesity or overweight and prediabetes who want to avoid progression to diabetes.
- Evidence
- No results yet. The ENLIGHTEN-1 phase 3 trial includes a longer extension to test this.
- Route
- ENLIGHTEN-1 trial (NCT07321886)
Obstructive sleep apnoea with obesity
- Who
- People with sleep apnoea and excess weight.
- Evidence
- No results yet. A phase 3 trial of about 800 people is authorised and recruiting.
- Route
- ENLIGHTEN-3 trial
Source: EU CTIS register, 2026
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Questions people ask
What is eloralintide?
A weekly injection from Eli Lilly that copies amylin, the fullness hormone released with insulin. Amylin drugs are being developed as a gentler alternative or partner to GLP-1.
How much weight loss did eloralintide give?
In a 263-person phase 2 trial over 48 weeks, loss ranged from 9.5% on the lowest dose to 20.1% on the highest, against 0.4% on placebo.
What are the side effects of eloralintide?
Mostly mild-to-moderate stomach symptoms and tiredness, more at higher doses. Longer-term safety is not known.
When will eloralintide be available?
It is not approved. Phase 3 trials began around the end of 2025 and are registered in obesity, diabetes and sleep apnea.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
Structure: PubChem